Cohance Lifesciences Limited (COHANCE) showcased a clear sequential recovery in its Q2 FY27 investor presentation, with revenue up 13% QoQ and adjusted EBITDA margin improving to 10% from 2% in Q1. The integrated capabilities of One Cohance are strengthening the growth platform.

Strategic Progress

The integration of One Cohance is driving operational and commercial progress across businesses. In the Pharma CDMO segment, the order and reload position for Q3 and Q4 has improved materially. Cohance secured two new commercial and one late-stage programme with large global pharma customers, strengthening relationships and medium-term growth opportunities. In the nucleic acid business, Sapala’s strong performance is supported by increasing integration of its specialised chemistry and customer relationships with Cohance’s development and manufacturing network.

Financial Performance

API+ revenue grew year-on-year, supported by selective pricing actions, while lower API volumes, shipment phasing, and higher raw-material costs impacted margins. Specialty Chemicals declined YoY due to lower AgChem volumes, pricing pressure, and programme phasing, while Performance Materials remained relatively stable. The company plans to announce investments in capex towards building capabilities in adjacencies and R&D to unlock the full potential of the One Cohance platform.

Looking Ahead

H2 FY27 revenue and EBITDA are expected to grow year-on-year, supported by continued recovery and progressive integration of Cohance’s capabilities to unlock platform potential. The H2 focus is on improving revenue mix and utilisation to support progressive margin recovery.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cohance Lifesciences Limited

Cohance Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cohance moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 5.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock holds at 30% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. The stock rises 5.0% in three months on 18.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Cohance Lifesciences Limited.

Fermenta Biotech Limited (FERMENTA) announced its financial results for Q2 FY27, showing a robust performance in the quarter. The company reported a revenue of INR 135.8 crore, up 8% from the previous quarter, and EBITDA increased by 3% QoQ to INR 23.2 crore.

Financial Highlights

The consolidated revenue for Q2 FY27 stood at INR 135.8 crore, a marginal increase of 0.1% year-on-year but an 8% rise quarter-over-quarter. The EBITDA for the quarter was INR 23.2 crore, showing a 3% QoQ growth. Profit after tax (PAT) for the quarter was INR 9.4 crore, down 48% YoY but down 1% QoQ.

Sector Performance

Human Nutrition, the primary revenue source, grew by 2% in H1 FY27 to INR 162.5 crore, contributing significantly to the overall revenue. India’s contribution to the half-year revenue rose to 51%, up from 40% a year earlier, reflecting the company’s expanding market presence.

Operational Milestones

Fermenta Biotech Limited achieved several milestones during the quarter, including the FSSAI approval for VITADEE Green® in July, the NSE listing in August, and securing an exclusive license for VIT Vellore Vitamin B12 in September. Looking ahead, the company expects to ramp up VITADEE Green® capacity from Q2 FY28 and aims to complete regulatory approvals for Calcifediol by the end of FY27.

Despite the challenges in the animal nutrition segment, Fermenta Biotech Limited continues to leverage its strengths in human nutrition and diversified markets to drive growth and maintain a low customer concentration, with the largest customer accounting for only 9% of revenue.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fermenta Biotech Limited

Fermenta Biotech Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Fermenta rises 12.3% over three months, with buying pressure holding steady. Revenue grows at 14.5% CAGR. The company generates cash but does not compound aggressively. The stock holds at 38% of its 52-week range with RSI at 43. In other words, neither side has a clear edge right now. Revenue grows at 14.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Fermenta Biotech Limited.

Sai Life Sciences Limited (NSE: SAILIFE) announced its financial results for the second quarter and half year ended September 2026, showcasing robust growth and operational efficiency. The company reported a revenue growth of 23% year-on-year (YoY), reaching ₹659 crore for Q2 FY27 compared to ₹537 crore in Q2 FY26. This growth was broad-based, with both Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) sectors delivering healthy performance.

Strong Financial Performance

The EBITDA margin remained stable at 28% for Q2 FY27, reflecting the company’s effective cost management and operational discipline. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at ₹187 crore, up 20% YoY. The profit after tax (PAT) also increased by 17% to ₹98 crore. The strong performance was driven by growing traction with global pharmaceutical companies and the increasing adoption of the company’s integrated outsourcing model.

Forward-Looking Outlook

Mr. Krishna Kanumuri, Managing Director and CEO, highlighted the company’s progress in building capacity and capabilities to support long-term customer relationships. The company continues to expect a stronger second half, supported by the progression of its development and commercial pipeline and the ramp-up of new capacity. The capacity and capability expansion program remains on track, with a total of ₹621 crore invested in H1 FY27.

As a result, Sai Life Sciences Limited is well-positioned to capitalize on emerging opportunities in the life sciences industry, maintaining its growth trajectory and delivering value to its stakeholders.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Life Sciences Limited

Sai Life Sciences Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Sai posts a 9.2% three-month gain, but softens in the last few weeks. The PEG of 0.36 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Revenue grows at 21.3% and profits at 226.9% CAGR. Both numbers are exceptional. RSI stands at 31, well into oversold territory. Yet sellers still dominated on 20 of recent sessions versus 10 for buyers, so the pressure has not fully lifted. Revenue grows at 21.3% and profits at 226.9%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Sai Life Sciences Limited.